About adc therapeutics sa - ADCT
ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.
ADCT At a Glance
ADC Therapeutics SA
Biopôle
Epalinges, Vaud 1066
| Phone | 41-212-653-02-00 | Revenue | 81.36M | |
| Industry | Pharmaceuticals: Major | Net Income | -142,623,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 14.851% | |
| Fiscal Year-end | 12 / 2026 | Employees | 193 | |
| View SEC Filings |
ADCT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 5.513 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -5.885 |
| Enterprise Value to Sales | 7.704 |
| Total Debt to Enterprise Value | 0.701 |
ADCT Efficiency
| Revenue/Employee | 421,538.86 |
| Income Per Employee | -738,979.275 |
| Receivables Turnover | 2.794 |
| Total Asset Turnover | 0.252 |
ADCT Liquidity
| Current Ratio | 4.366 |
| Quick Ratio | 4.306 |
| Cash Ratio | 3.725 |
ADCT Profitability
| Gross Margin | 90.567 |
| Operating Margin | -133.214 |
| Pretax Margin | -175.498 |
| Net Margin | -175.305 |
| Return on Assets | -44.161 |
| Return on Equity | N/A |
| Return on Total Capital | -56.214 |
| Return on Invested Capital | -168.623 |
ADCT Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 173.245 |
| Total Debt to Total Assets | 135.689 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 171.851 |